Lumen Loss at 1 Year After Bare Nitinol Stent Implantation in the Superficial Femoral Artery

Abstract

Purpose

To investigate lumen loss (LL) at 1 year after bare nitinol stent (BNS) implantation for de novo superficial femoral artery (SFA) lesions.

Materials and Methods

The subjects were 701 consecutive patients (mean age 74±9 years; 492 men) with 817 de novo SFA lesions treated with BNS implantation between January 2004 and September 2015. The mean lesion length was 141±88 mm and the mean vessel diameter was 5.4±0.9 mm. The endpoint was LL at 1 year after BNS implantation. Secondary outcomes were restenosis and target lesion revascularization (TLR) estimated using the Kaplan-Meier method; estimates are reported with the 95% confidence interval (CI). LL was defined as the minimum lumen diameter immediately after BNS implantation minus that at 1 year measured by angiographic quantitative vessel analysis. The distribution of LL in the overall population was estimated using an accelerated failure time model.

Results

Mean LL at 1 year was estimated to be 1.74±1.28 mm (95% CI 1.63 to 1.84). Current smoking was positively associated with LL (p=0.015), whereas lack of cilostazol use was correlated with an increase in LL (p=0.001). Reference vessel diameter and lesion length did not have any significant association with LL at 1 year. The 1-year cumulative estimate of restenosis was 25% (95% CI 22% to 28%); the corresponding value for TLR was 18% (95% CI 15% to 21%).

Conclusion

Mean LL progressed by at least 1.6 mm up to 1 year after BNS implantation. The risk factors for increased LL were current smoker and lack of cilostazol use.

Keywords

angioplasty bare metal stent cilostazol endovascular therapy femoropopliteal segment lumen loss smoking superficial femoral artery

Get full access to this article

View all access options for this article.

References

Schillinger

Sabeti

Loewe

, et al. Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery. N Engl J Med. 2006;354:1879–1888.

Vogel

Shindelman

Nackman

, et al. Efficacious use of nitinol stents in the femoral and popliteal arteries. J Vasc Surg. 2003;38:1178–1184.

Dick

Wallner

Sabeti

, et al. Balloon angioplasty versus stenting with nitinol stents in intermediate length superficial femoral artery lesions. Catheter Cardiovasc Interv. 2009;74:1090–1095.

Laird

Katzen

Scheinert

, et al. Nitinol stent implantation versus balloon angioplasty for lesions in the superficial femoral artery and proximal popliteal artery: twelve-month results from the RESILIENT randomized trial. Circ Cardiovasc Interv. 2010;3:267–276.

Muller-Hulsbeck

Keirse

Zeller

, et al. Long-term results from the MAJESTIC trial of the Eluvia paclitaxel-eluting stent for femoropopliteal treatment: 3-year follow-up. Cardiovasc Intervent Radiol. 2017;40:1832–1838.

Dake

Ansel

Jaff

, et al. Durable clinical effectiveness with paclitaxel-eluting stents in the femoropopliteal artery: 5-year results of the Zilver PTX randomized trial. Circulation. 2016;133:1472–1483.

Morice

Serruys

Sousa

, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002;346:1773–1780.

Stone

Ellis

Cox

, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med. 2004;350:221–231.

Scheller

Hehrlein

Bocksch

, et al. Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. N Engl J Med. 2006;355:2113–2124.

10.

van der Hoeven

Liem

Jukema

, et al. Sirolimus-eluting stents versus bare-metal stents in patients with ST-segment elevation myocardial infarction: 9-month angiographic and intravascular ultrasound results and 12-month clinical outcome results from the MISSION! Intervention Study. J Am Coll of Cardiol. 2008;51:618–626.

11.

Kimura

Kozuma

Tanabe

, et al. A randomized trial evaluating everolimus-eluting Absorb bioresorbable scaffolds vs. everolimus-eluting metallic stents in patients with coronary artery disease: ABSORB Japan. Eur Heart J. 2015;36:3332–3342.

12.

Teeuwen

van der Schaaf

Adriaenssens

, et al. Randomized multicenter trial investigating angiographic outcomes of hybrid sirolimus-eluting stents with biodegradable polymer compared with everolimus-eluting stents with durable polymer in chronic total occlusions: the PRISON IV trial. JACC Cardiovascular Interv. 2017;10:133–143.

13.

Soga

Fujihara

Tomoi

, et al. One-year late lumen loss between a polymer-coated paclitaxel-eluting stent (Eluvia) and a polymer-free paclitaxel-coated stent (Zilver PTX) for femoropopliteal disease. J Atheroscler Thromb. 2020;27:164–171.

14.

Hiramori

Soga

Iida

, et al. Relationship between clinical outcomes and vessel size in endovascular therapy for femoropopliteal lesions. J Vasc Surg. 2017;65:1690–1697.

15.

Soga

Takahara

Iida

, et al. Relationship between primary patency and lesion length following bare nitinol stent placement for femoropopliteal disease. J Endovasc Ther. 2015;22:862–867.

16.

Iida

Uematsu

Soga

, et al. Timing of the restenosis following nitinol stenting in the superficial femoral artery and the factors associated with early and late restenoses. Catheter Cardiovasc Interv. 2011;78:611–617.

17.

Soga

Iida

Hirano

, et al. Mid-term clinical outcome and predictors of vessel patency after femoropopliteal stenting with self-expandable nitinol stent. J Vasc Surg. 2010;52:608–615.

18.

Willigendael

Teijink

Bartelink

, et al. Smoking and the patency of lower extremity bypass grafts: a meta-analysis. J Vasc Surg. 2005;42:67–74.

19.

Shiraki

Iida

Inoue

, et al. Very late histopathologic evaluation of neointimal characteristics after bare-metal stent implantation in the superficial femoral artery. J Vasc Interv Radiol. 2019;30:616–617.